Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
The IMID Forum
14 minutes 37 seconds
2 weeks ago
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
The IMID Forum
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
